These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10509175)

  • 21. [Cognitive aging in schizophrenia].
    Bazin N
    Geriatr Psychol Neuropsychiatr Vieil; 2011 Sep; 9(3):337-44. PubMed ID: 21896436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gender differences in poor outcome patients with lifelong schizophrenia.
    Moriarty PJ; Lieber D; Bennett A; White L; Parrella M; Harvey PD; Davis KL
    Schizophr Bull; 2001; 27(1):103-13. PubMed ID: 11215540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicians' concepts of the cognitive deficits of schizophrenia.
    Bromley E
    Schizophr Bull; 2007 May; 33(3):648-51. PubMed ID: 17420175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What do we know about neuropsychological aspects of schizophrenia?
    Palmer BW; Dawes SE; Heaton RK
    Neuropsychol Rev; 2009 Sep; 19(3):365-84. PubMed ID: 19639412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mild cognitive impairment: focus on diagnosis.
    de Mendonça A; Guerreiro M; Ribeiro F; Mendes T; Garcia C
    J Mol Neurosci; 2004; 23(1-2):143-8. PubMed ID: 15126699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing cognitive function in schizophrenics and patients with Alzheimer's disease.
    Mohs RC
    Schizophr Res; 1995 Sep; 17(1):115-21. PubMed ID: 8541244
    [No Abstract]   [Full Text] [Related]  

  • 27. Insight into neurocognitive dysfunction in schizophrenia.
    Medalia A; Thysen J
    Schizophr Bull; 2008 Nov; 34(6):1221-30. PubMed ID: 18199632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
    Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
    Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic variables at intake and long-term level of function in schizophrenia.
    Siegel SJ; Irani F; Brensinger CM; Kohler CG; Bilker WB; Ragland JD; Kanes SJ; Gur RC; Gur RE
    Am J Psychiatry; 2006 Mar; 163(3):433-41. PubMed ID: 16513864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
    Perlick DA; Rosenheck RA; Kaczynski R; Bingham S; Collins J
    Schizophr Res; 2008 Feb; 99(1-3):192-9. PubMed ID: 17851042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique.
    Allott K; Liu P; Proffitt TM; Killackey E
    Schizophr Res; 2011 Feb; 125(2-3):221-35. PubMed ID: 21111577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropsychiatric impairments as predictors of mild cognitive impairment, dementia, and Alzheimer's disease.
    Stepaniuk J; Ritchie LJ; Tuokko H
    Am J Alzheimers Dis Other Demen; 2008; 23(4):326-33. PubMed ID: 18453641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurocognitive deficit changes in relation to the course of schizophrenia and schizophrenia spectrum disorders: 5-year follow-up study.
    Zaytseva Y; Korsakova NK; Gurovich IY
    Psychiatr Danub; 2010 Nov; 22 Suppl 1():S149-51. PubMed ID: 21057427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-validation of the Florida Cognitive Activities Scale (FCAS) in an Alzheimer's disease research center sample.
    Schinka JA; Raj A; Loewenstein DA; Small BJ; Duara R; Potter H
    J Geriatr Psychiatry Neurol; 2010 Mar; 23(1):9-14. PubMed ID: 19703991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Senile degeneration and cognitive impairment in chronic schizophrenia.
    Dwork AJ; Susser ES; Keilp J; Waniek C; Liu D; Kaufman M; Zemishlany Z; Prohovnik I
    Am J Psychiatry; 1998 Nov; 155(11):1536-43. PubMed ID: 9812114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients.
    Harvey PD; Silverman JM; Mohs RC; Parrella M; White L; Powchik P; Davidson M; Davis KL
    Biol Psychiatry; 1999 Jan; 45(1):32-40. PubMed ID: 9894573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parahippocampal volume deficits in subjects with aging-associated cognitive decline.
    Pantel J; Kratz B; Essig M; Schröder J
    Am J Psychiatry; 2003 Feb; 160(2):379-82. PubMed ID: 12562591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognition and aging in psychopathology: focus on schizophrenia and depression.
    Harvey PD; Reichenberg A; Bowie CR
    Annu Rev Clin Psychol; 2006; 2():389-409. PubMed ID: 17716076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment].
    Lecardeur L; Meunier-Cussac S; Dollfus S
    Encephale; 2013 May; 39 Suppl 1():S64-71. PubMed ID: 23528322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen replacement therapy: effects on the cognitive functioning and clinical course of women with Alzheimer's disease.
    Levine AJ; Battista M
    Arch Clin Neuropsychol; 2004 Sep; 19(6):769-78. PubMed ID: 15288330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.